Progress in the treatment of NK-cell lymphoma/leukemia

作     者：Ayumi Fujimoto Ritsuro Suzuki Ayumi Fujimoto;Ritsuro Suzuki

作者机构：Department of HematologyShimane University HospitalIzumoShimane 693-8501Japan 

出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)

年 卷 期：2021年第7卷第1期

页      面：901-914页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Extranodal NK/T-cell lymphoma nasal type aggressive NK-cell leukemia Epstein-Barr virus hematopoietic stem cell transplantation L-asparaginase 

摘      要：Natural killer(NK)/T cell lymphoma includes two major subtypes of disease,specifically extranodal NK/T cell lymphoma,nasal type(ENKL)and aggressive NK cell leukemia(ANKL).Both are strongly associated with Epstein Barr virus and are prevalent in East Asia and Latin *** for that of limited-stage ENKL,the prognosis of both diseases was poor in the previous *** advent of non-anthracycline-based chemoradiotherapy has contributed to an improvement in ENKL prognosis,but there is still room for further treatment ***,the high efficacy of PD-1 antibody was reported in relapsed or refractory ENKL *** was later supported by the finding that PD-L1/PD-L2 genetic alterations are frequently observed in ENKL and ANKL *** to the rarity of the disease,a standard treatment for ANKL remains to be ***,allogeneic stem cell transplantation is the only curative treatment,and this is even applicable to chemo-resistant ANKL *** this review,we focus on recent treatment approaches for NK/T cell lymphomas including novel agents.